DEBIOPHARM INTERNATIONAL SA. Lausanne, Switzerland
NARROW SPECTRUM FABI INHIBITOR
Direct-Acting Small Molecule Therapeutic
Debiopharm International SA, a Swiss-headquartered global biopharmaceutical company, has developed a novel class of antibiotics which inhibit bacterial fatty acid biosynthesis, an essential pathway in major pathogens including Neisseria gonorrhoeae, the causative bacterium in the sexually transmitted disease gonorrhea. N. gonorrhoeae’s resistance to antibiotics is a major global medical problem having acquired resistance to practically all classes of antibiotics (CDC). Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics drug discovery platform to develop novel therapeutics to combat drug-resistant gonorrhea.
Current Development Stage: Pre-clinical
CARB-X Investment: Initial investment of up to $2.6m with potential option payments up to $1.4m.
Initial CARB-X Investment Date: July 1, 2017